2500 Westchester Ave.
Purchase, NY 10577
United States
412 481 2210
https://www.cogrx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 25
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Lisa Ricciardi | CEO, President & Director | 854,15k | N/D | 1960 |
Mr. John Brendan Doyle | Chief Financial Officer | 414,88k | N/D | 1977 |
Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer and Head of R&D | 616,27k | N/D | 1970 |
Dr. Steven A. Weissman Ph.D. | VP & Head of CMC | N/D | N/D | N/D |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
L'ISS Governance QualityScore di Cognition Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.